Transcode Therapeutics (RNAZ) Current Leases (2023 - 2024)
Transcode Therapeutics' (RNAZ) quarterly Current Leases came in at $38291.0 in Q4 2024, down 90.71% YoY from $412280.0 in Q1 2024, and down 74.89% on a QoQ basis from $152481.0 in Q3 2024.
Transcode Therapeutics (RNAZ) Current Leases (2023 - 2024) Analysis & Trends
Transcode Therapeutics (RNAZ) has 2 years of Current Leases data on file, last reported at $38291.0 in Q4 2024.
- Quarterly Current Leases fell 90.71% year-over-year to $38291.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $38291.0 (down 90.71% YoY) and the FY2024 annual result came in at $38291.0, down 90.71% from the prior year.
- Current Leases eased to $38291.0 in Q4 2024, from $152481.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $412280.0 in Q4 2023 to a low of $38291.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | - |
| 10 | Transcode Therapeutics | 2.80 Mn | 2.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 38,291.00 |
| Sep 30, 2024 | 152,481.00 |
| Jun 30, 2024 | 227,246.00 |
| Mar 31, 2024 | 339,408.00 |
| Dec 31, 2023 | 412,280.00 |
| Sep 30, 2023 | 404,928.00 |
| Jun 30, 2023 | 397,641.00 |
| Mar 31, 2023 | 390,419.00 |